Recent research have converged on the convergence of glucagon-like peptide-1|GIP|GCGR activator therapies and dopamine signaling. While GLP stimulators are increasingly employed for managing type 2 diabetes mellitus, their emerging effects on motivation circuits, specifically influenced by dopami